Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MyPeBS

Financiado

Cerrado

International Randomized Study Comparing personalized Risk Stratified to Standa...

International Randomized Study Comparing personalized Risk Stratified to Standard Breast Cancer Screening In Women Aged 40 70 MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite... ver más

30/06/2026

MINISTERE DE L'ENS...

12M€

Presupuesto del proyecto: 12M€

Líder del proyecto

MINISTERE DE L'ENSEIGNEMENT SUPERIEUR ET DE... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 33 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-12-05

SC1-PM-10-2017: Comparing the effectiveness of exis...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

33 Participantes

MINISTERE DE L'ENSEIGNEMENT...

3.12M€ | Lider

ERCROS

637.41K€ | Participante

QMUL

102.71K€ | Participante

ISPRO

196.83K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ASSURE Adapting Breast Cancer Screening Strategy Using Personalised... 7M€ Cerrado

EU-TOPIA EU TOPIA TOWARDS IMPROVED SCREENING FOR BREAST CERVICAL AN... 3M€ Cerrado

DPI2015-68442-R ANALISIS DE IMAGENES INTELIGENTE PARA LOS RETOS EN EL CRIBAD... 138K€ Cerrado

ONCOSCREEN A European shield against colorectal cancer based on novel,... 13M€ Cerrado

ONCOSCREEN A European “shield” against colorectal cancer based on novel... 13M€ Cerrado

MammaPrint Improved breast cancer care by innovative diagnostic test Ma... 4M€ Cerrado

Duración del proyecto: 102 meses Fecha Inicio: 2017-12-05
Fecha Fin: 2026-06-30

Líder del proyecto

MINISTERE DE L'ENSEIGNEMENT SUPERIEUR ET DE... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 12M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite a demonstrated mean 20% reduction in breast cancer-specific mortality, together with reduction of late-stage disease in women older than 50, it is associated with potential harms including false positive recalls and over-diagnosis. Individual breast cancer risk estimation, through models including clinical variables, mammographic breast density and more than 100 genetic polymorphisms, now has substantial clinical and scientific bases. Personalized screening strategies, based on individual risk levels, could potentially improve the individual benefit/harms ratio of screening (earlier cancer detection and less intensive treatments in high risk women, less false positives and over-diagnoses in low risk ones), and increase the cost-efficacy for health insurances. MyPEBS will conduct an international randomized phase III trial to validate this hypothesis. It will primarily assess the ability of an individual risk-based screening strategy to be non-inferior, and possibly superior, to the standard of care screening, in reducing the cumulative incidence of stage II+ breast cancers. The trial, conducted in 5 countries (France, Italy, UK, Belgium and Israel) will include 85000 European women aged 40-70, all followed for 4 years. MyPEBS will also evaluate if an individual risk-based screening strategy, compared with the standard, reduces screening-related harms (unnecessary biopsies, overdiagnoses) in low-risk women, is overall at least as cost-effective as well as more accepted by women resulting in a larger screening coverage. After analyses of all components, the final objective of MyPEBS is to deliver recommendations for the best future breast cancer screening strategy in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores